Effects of Single-dose Atorvastatin on Interleukin-6, Interferon Gamma, and Myocardial No-reflow in a Rabbit Model of Acute Myocardial Infarction and Reperfusion

Overview

Journal Braz J Med Biol Res

Specialties Biology
General Medicine

Date 2014 Feb 21

PMID 24554037

Citations 6

Authors

X J Zhao

X L Liu

G X He

H P Xu

Affiliations

Soon will be listed here.

Abstract

The mechanisms of statins relieving the no-reflow phenomenon and the effects of single-dose statins on it are not well known. This study sought to investigate the effects of inflammation on the no-reflow phenomenon in a rabbit model of acute myocardial infarction and reperfusion (AMI/R) and to evaluate the effects of single-dose atorvastatin on inflammation and myocardial no-reflow. Twenty-four New Zealand white male rabbits (5-6 months old) were randomized to three groups of eight: a sham-operated group, an AMI/R group, and an atorvastatin-treated group (10 mg/kg). Animals in the latter two groups were subjected to 4 h of coronary occlusion followed by 2 h of reperfusion. Serum levels of interleukin (IL)-6 were measured by enzyme-linked immunosorbent assay. The expression of interferon gamma (IFN-γ) in normal and infarcted (reflow and no-reflow) myocardial tissue was determined by immunohistochemical methods. The area of no-reflow and necrosis was evaluated pathologically. Levels of serum IL-6 were significantly lower in the atorvastatin group than in the AMI/R group (P<0.01). Expression of IFN-γ in infarcted reflow and no-reflow myocardial tissue was also significantly lower in the atorvastatin group than in the AMI/R group. The mean area of no-reflow [47.01% of ligation area (LA)] was significantly smaller in the atorvastatin group than in the AMI/R group (85.67% of LA; P<0.01). The necrosis area was also significantly smaller in the atorvastatin group (85.94% of LA) than in the AMI/R group (96.56% of LA; P<0.01). In a secondary analysis, rabbits in the atorvastatin and AMI/R groups were divided into two groups based on necrosis area (90% of LA): a small group (<90% of LA) and a large group (>90% of LA). There was no significant difference in the area of no-reflow between the small (61.40% of LA) and large groups (69.87% of LA; P>0.05). Single-dose atorvastatin protected against inflammation and myocardial no-reflow and reduced infarct size during AMI/R in rabbits. No-reflow was not dependent on the reduction of infarct size.

Citing Articles

Enhancing growing rabbit heat stress resilience through dietary supplementation with natural antioxidants.

El-Ratel I, Mekawy A, Hassab S, Abdelnour S BMC Vet Res. 2025; 21(1):28.

PMID: 39827123 PMC: 11748597. DOI: 10.1186/s12917-024-04466-1.

Cytokine Pathways in Cardiac Dysfunction following Burn Injury and Changes in Genome Expression.

Dejesus J, Wen J, Radhakrishnan R J Pers Med. 2022; 12(11).

PMID: 36579591 PMC: 9696755. DOI: 10.3390/jpm12111876.

Trial of Atorvastatin on Serum Interleukin-6, Total Antioxidant Capacity, C-Reactive Protein, and Alpha-1 Antitrypsin in Patients with Chronic Obstructive Pulmonary Disease.

Arian A, Mortazavi Moghadam S, Kazemi T, Zardast M, Zarban A J Res Pharm Pract. 2018; 7(3):141-146.

PMID: 30211239 PMC: 6121763. DOI: 10.4103/jrpp.JRPP_17_93.

Effects of remote ischemic post-conditioning on platelet activation of AMI patients.

Qian Y, Dai K, Zhao L, Yang X Exp Ther Med. 2018; 16(2):1273-1277.

PMID: 30112058 PMC: 6090423. DOI: 10.3892/etm.2018.6280.

Role of cytokines and inflammation in heart function during health and disease.

Bartekova M, Radosinska J, Jelemensky M, Dhalla N Heart Fail Rev. 2018; 23(5):733-758.

PMID: 29862462 DOI: 10.1007/s10741-018-9716-x.

References

Briguori C, Colombo A, Airoldi F, Violante A, Focaccio A, Balestrieri P . Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur Heart J. 2004; 25(20):1822-8. DOI: 10.1016/j.ehj.2004.07.017. View

Gurgun C, Ildizli M, Yavuzgil O, Sin A, Apaydin A, Cinar C . The effects of short term statin treatment on left ventricular function and inflammatory markers in patients with chronic heart failure. Int J Cardiol. 2007; 123(2):102-7. DOI: 10.1016/j.ijcard.2006.11.152. View

Nohria A, Prsic A, Liu P, Okamoto R, Creager M, Selwyn A . Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis. 2009; 205(2):517-21. PMC: 2717178. DOI: 10.1016/j.atherosclerosis.2008.12.023. View

Schwartz B, Kloner R . Coronary no reflow. J Mol Cell Cardiol. 2011; 52(4):873-82. DOI: 10.1016/j.yjmcc.2011.06.009. View

Gibson C, Cannon C, Murphy S, Ryan K, Mesley R, MARBLE S . Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 2000; 101(2):125-30. DOI: 10.1161/01.cir.101.2.125. View

Stumpf C, Petzi S, Seybold K, Wasmeier G, Arnold M, Raaz D . Atorvastatin enhances interleukin-10 levels and improves cardiac function in rats after acute myocardial infarction. Clin Sci (Lond). 2008; 116(1):45-52. DOI: 10.1042/CS20080042. View

Yeh E, Anderson H, Pasceri V, Willerson J . C-reactive protein: linking inflammation to cardiovascular complications. Circulation. 2001; 104(9):974-5. DOI: 10.1161/01.cir.104.9.974. View

Gaddam V, Li D, Mehta J . Anti-thrombotic effects of atorvastatin--an effect unrelated to lipid lowering. J Cardiovasc Pharmacol Ther. 2002; 7(4):247-53. DOI: 10.1177/107424840200700408. View

Link A, Ayadhi T, Bohm M, Nickenig G . Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. Eur Heart J. 2006; 27(24):2945-55. DOI: 10.1093/eurheartj/ehl277. View

10.

Sakabe K, Fukuda N, Wakayama K, Nada T, Shinohara H, Tamura Y . Lipid-altering changes and pleiotropic effects of atorvastatin in patients with hypercholesterolemia. Am J Cardiol. 2004; 94(4):497-500. DOI: 10.1016/j.amjcard.2004.04.067. View

11.

Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G . Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol. 2007; 49(12):1272-8. DOI: 10.1016/j.jacc.2007.02.025. View

12.

Wang C, Liu P, Liao J . Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med. 2007; 14(1):37-44. PMC: 2621332. DOI: 10.1016/j.molmed.2007.11.004. View

13.

Kloner R . No-reflow phenomenon: maintaining vascular integrity. J Cardiovasc Pharmacol Ther. 2011; 16(3-4):244-50. DOI: 10.1177/1074248411405990. View

14.

Helmy S, Wahby M . The effect of anaesthesia and surgery on plasma cytokine production. Anaesthesia. 1999; 54(8):733-8. DOI: 10.1046/j.1365-2044.1999.00947.x. View

15.

Shen Y, Wu H, Wang C, Shao H, Huang H, Jing H . Simvastatin attenuates cardiopulmonary bypass-induced myocardial inflammatory injury in rats by activating peroxisome proliferator-activated receptor γ. Eur J Pharmacol. 2010; 649(1-3):255-62. DOI: 10.1016/j.ejphar.2010.08.058. View

16.

Herrmann J . Peri-procedural myocardial injury: 2005 update. Eur Heart J. 2005; 26(23):2493-519. DOI: 10.1093/eurheartj/ehi455. View

17.

Wolfrum S, Dendorfer A, Schutt M, Weidtmann B, Heep A, Tempel K . Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway. J Cardiovasc Pharmacol. 2004; 44(3):348-55. DOI: 10.1097/01.fjc.0000137162.14735.30. View

18.

Meijer P, Oyen W, Dekker D, van den Broek P, Wouters C, Boerman O . Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection. Arterioscler Thromb Vasc Biol. 2009; 29(6):963-8. DOI: 10.1161/ATVBAHA.108.179622. View

19.

Li X, Yang Y, Geng Y, Zhao J, Zhang H, Cheng Y . Phosphorylation of endothelial NOS contributes to simvastatin protection against myocardial no-reflow and infarction in reperfused swine hearts: partially via the PKA signaling pathway. Acta Pharmacol Sin. 2012; 33(7):879-87. PMC: 4011153. DOI: 10.1038/aps.2012.27. View

20.

Zhang A, Zhang H, Wu S . Immunomodulation by atorvastatin upregulates expression of gap junction proteins in coxsackievirus B3 (CVB3)-induced myocarditis. Inflamm Res. 2009; 59(4):255-62. DOI: 10.1007/s00011-009-0093-8. View